LTRN Lantern Pharma Inc

Price (delayed)

$4.38

Market cap

$47.12M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.63

Enterprise value

$28.96M

Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. It leverages advances in machine learning, genomics, and artificial intelligence by ...

Highlights
The company's debt fell by 26% YoY and by 17% QoQ
The quick ratio has contracted by 48% YoY and by 37% from the previous quarter
The equity has contracted by 32% YoY and by 13% from the previous quarter

Key stats

What are the main financial stats of LTRN
Market
Shares outstanding
10.76M
Market cap
$47.12M
Enterprise value
$28.96M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.32
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$17.53M
EBITDA
-$17.36M
Free cash flow
-$13.67M
Per share
EPS
-$1.63
Free cash flow per share
-$1.27
Book value per share
$3.33
Revenue per share
$0
TBVPS
$3.7
Balance sheet
Total assets
$39.73M
Total liabilities
$3.97M
Debt
$193,584
Equity
$35.77M
Working capital
$35.52M
Liquidity
Debt to equity
0.01
Current ratio
9.98
Quick ratio
9.7
Net debt/EBITDA
1.05
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-38.4%
Return on equity
-41.2%
Return on invested capital
-91.3%
Return on capital employed
-49%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LTRN stock price

How has the Lantern Pharma stock price performed over time
Intraday
-0.9%
1 week
7.62%
1 month
-18.44%
1 year
-11.52%
YTD
2.34%
QTD
-6.21%

Financial performance

How have Lantern Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.32M
Net income
-$17.53M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 32% year-on-year and by 8% since the previous quarter
The company's net income fell by 25% YoY and by 10% QoQ

Growth

What is Lantern Pharma's growth rate over time

Valuation

What is Lantern Pharma stock price valuation
P/E
N/A
P/B
1.32
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Lantern Pharma's EPS has decreased by 26% YoY and by 11% from the previous quarter
LTRN's price to book (P/B) is 37% lower than its 5-year quarterly average of 2.1 and 11% lower than its last 4 quarters average of 1.5
The equity has contracted by 32% YoY and by 13% from the previous quarter

Efficiency

How efficient is Lantern Pharma business performance
The ROE has plunged by 68% YoY and by 21% from the previous quarter
Lantern Pharma's return on assets has shrunk by 66% YoY and by 19% QoQ
The return on invested capital has declined by 22% year-on-year and by 13% since the previous quarter

Dividends

What is LTRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LTRN.

Financial health

How did Lantern Pharma financials performed over time
The current ratio has declined by 49% year-on-year and by 38% since the previous quarter
The quick ratio has contracted by 48% YoY and by 37% from the previous quarter
The company's debt is 99% lower than its equity
The equity has contracted by 32% YoY and by 13% from the previous quarter
The company's debt fell by 26% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.